The cleavage of C3 and C5 into distinct functional fragments is the pivotal event that both drives the complement effector response and provides a diagnostic window into its activation.
C3 is cleaved into C3a—a fluid‑phase anaphylatoxin and chemotaxin—and C3b—a surface‑attached opsonin that marks cells for phagocytosis. C5 is subsequently cleaved into C5a, the most potent anaphylatoxin and neutrophil chemoattractant, and C5b, which binds the target surface to seed the assembly of the membrane attack complex (MAC). Selecting one of these cleavage products as the analyte immediately defines what stage of the cascade you are measuring, and it dictates the design of antibodies, protein standards, and sample handling protocols for a quantitative immunoassay.
The central takeaway: The identity of the C3 and C5 fragment you target determines whether you report on early‑stage inflammation (C3a/C5a), opsonophagocytic defence (C3b), or terminal lytic activation (C5b). Matching the fragment to the clinical question is the first strategic choice in developing a high‑specificity complement diagnostic.
The Cleavage Products of C3 and C5: A Functional Overview
The Split of C3: Anaphylatoxin and Opsonin
When C3 convertase cleaves C3, a small peptide—C3a—is released into the fluid phase.
C3a acts as an anaphylatoxin: it binds mast cells and triggers degranulation, increasing vascular permeability and driving neutrophil chemotaxis.
The larger fragment, C3b, is deposited directly onto activating surfaces.
It serves as a potent opsonin, coating microbial or cellular targets to enhance phagocytosis via complement receptors (CR3, CR4) on macrophages and neutrophils.
Through its binding to the target, C3b also becomes the scaffold for C5 convertase formation, bridging the cascade toward terminal activation.
The Split of C5: Potent Inflammatory Signal and Lysis Initiation
C5 is cleaved by the C5 convertase to yield C5a, the most powerful anaphylatoxin in the cascade.
C5a surpasses C3a in strength: it not only drives histamine release but also directly attracts and activates neutrophils, stimulates oxidative burst, and induces kallikrein‑mediated bradykinin production.
C5b remains attached to the activating surface, where it sequentially recruits C6, C7, C8, and multiple C9 molecules.
The resulting C5b‑9 complex (MAC) inserts into the lipid bilayer, creating lytic pores that can destroy targeted pathogens or, in dysregulated contexts, host cells.
How These Fragments Guide Biomarker Selection in Immunoassay Development
Targeting Soluble Anaphylatoxins (C3a, C5a) for Systemic Inflammation
C3a and C5a appear in plasma as immediate, soluble readouts of complement activation.
Their rapid generation makes them ideal biomarkers for hyper‑inflammatory states such as sepsis, auto‑immune flare‑ups, and acute respiratory distress syndrome.
Assays for these anaphylatoxins require high‑affinity monoclonal capture antibodies and recombinant peptide standards that are free of cross‑reaction with native, uncleaved C3 or C5.
Because these are soluble, low‑molecular‑weight peptides, ELISA and multiplex platforms can directly quantify them in serum or plasma with minimal sample manipulation.
Targeting Surface‑Bound C3b for Opsonization and Immune Complex Monitoring
C3b (and its further‑cleaved derivative iC3b) indicates that a surface has been targeted for phagocytosis.
Measuring C3b or iC3b is valuable when the diagnostic goal is to evaluate opsonophagocytic function, immune complex clearance, or the local activation state in tissue‑based samples.
Designing an assay for C3b presents a different challenge: the fragment is surface‑bound.
Detection often requires flow cytometry or immunohistochemistry, using antibodies that discriminate between intact C3 and its activation product C3b.
Purified C3b (or recombinant mimics) serves as the standard, and the capture antibody pair must be carefully validated against C3d‑containing fragments to avoid underestimating opsonin load.
Targeting C5b and the MAC for Terminal Pathway Assessment
Detecting the C5b‑9 neo‑epitope—exposed only when C5b associates with C6–C9—confirms that the cascade has progressed to cytolysis.
Soluble C5b‑9 complexes can be measured in body fluids as a biomarker of terminal pathway activity, while tissue‑deposited MAC is assessed by immunohistology.
An assay for C5b‑9 relies on monoclonal antibodies that recognize a neo‑epitope unique to the assembled MAC, not the individual components.
Quality standards are typically purified, in‑vitro‑formed MAC complexes.
This approach delivers high specificity for terminal activation, but it requires strict control of sample handling to prevent ex‑vivo assembly.
Pathway‑Specific Considerations for Assay Design
Classical vs. Alternative Convertase Products
Although all pathways converge on C3 cleavage, the enzyme complexes that generate the fragments differ.
The classical/lectin pathway uses the C4bC2a convertase (cleaving C3) and C4bC2aC3b (cleaving C5), while the alternative pathway relies on C3bBb and C3bBbC3b.
For diagnostic labs, measuring C3a and C5a alone provides a pan‑activation signal, but adding C4d as a marker can distinguish classical/lectin pathway involvement from purely alternative pathway activation.
Selecting the right supporting biomarker allows IVD manufacturers to design pathway‑specific functional assays (e.g., CH50 or AH50) or multiplex panels that map the route of activation.
Selecting Raw Materials: Recombinant Proteins, Purified Standards, and Monoclonal Antibodies
Building a robust immunoassay demands a thoughtful match between the cleavage fragment and the raw materials.
Developers use recombinant anaphylatoxin peptides (C3a, C5a) as calibrators, purified C3b or iC3b as surface‑bound analyte standards, and monoclonal capture antibodies raised against activation‑specific neo‑epitopes.
The antibody pair must not recognize the intact parent protein; otherwise, the assay loses specificity for activation.
Likewise, protein standards must reflect the exact cleavage state, because artificial truncation or degradation can shift the dose‑response curve and compromise accuracy.
Understanding the Trade‑offs
Choosing a biomarker among C3 and C5 fragments involves balancing clinical insight with practical assay constraints.
Anaphylatoxins (C3a, C5a) offer exceptional sensitivity for acute inflammation but are extremely short‑lived in circulation, requiring careful plasma stabilization and rapid processing.
C3b and iC3b provide a direct window into opsonization and immune complex handling, yet their surface‑bound nature limits throughput and demands specialized detection platforms (flow cytometry, tissue staining).
Standardizing these assays is more complex because the analyte is not readily soluble.
C5b‑9 (MAC) is a definitive marker of terminal pathway activation, but its measurement can be confounded by ex‑vivo complement activation if blood collection tubes lack appropriate inhibitors.
Additionally, terminal assays tell you nothing about early anaphylatoxin generation or opsonic capacity.
Furthermore, any assay that targets a cleaved fragment must contend with the tremendous concentration difference between the abundant native protein (C3, C5) and the low‑level activation product, raising the bar for antibody specificity and assay dynamic range.
Making the Right Choice for Your Diagnostic Goal
Match the cleavage fragment to the specific pathological process you need to monitor.
- If your primary focus is detecting acute systemic inflammation (sepsis, anaphylaxis, cytokine storm): Prioritize soluble C3a and C5a immunoassays with high‑affinity neo‑epitope antibodies and stabilized recombinant standards.
- If your primary focus is evaluating opsonophagocytic competence or immune‑complex clearance: Target C3b/iC3b deposition on cellular targets using flow‑based or solid‑phase assays, paired with purified C3b calibrators.
- If your primary focus is confirming terminal pathway activation and MAC‑mediated tissue injury: Measure C5b‑9 neo‑epitope complexes in plasma or tissue stains, using MAC‑specific antibodies and in‑vitro‑formed MAC standards.
- If your primary focus is distinguishing classical, lectin, or alternative pathway defects: Combine C3a/C5a profiling with pathway‑specific convertase intermediates (C4d for classical/lectin, Bb for alternative) to isolate the route of activation.
By mapping the unique roles of each C3 and C5 cleavage fragment—anaphylatoxin, opsonin, MAC initiator—you transform a complex proteolytic cascade into actionable diagnostic endpoints that directly answer your clinical question.
Summary Table:
| Fragment | Primary Functional Role | Clinical Diagnostic Target | Key Immunoassay Consideration |
|---|---|---|---|
| C3a / C5a | Fluid-phase anaphylatoxins & neutrophil chemoattractants | Acute systemic inflammation (Sepsis, ARDS, Autoimmune flares) | Requires neo-epitope specific antibodies to avoid cross-reactivity with native C3/C5. |
| C3b / iC3b | Surface-bound opsonins for phagocytosis & convertase assembly | Opsonophagocytic competence & immune complex clearance | Evaluated via surface methods (Flow Cytometry/IHC); requires discriminating mAb pairs. |
| C5b-9 (MAC) | Terminal lytic pore complex inducing cell lysis | Terminal pathway activation & MAC-mediated tissue injury | Target unique MAC neo-epitopes; sample collection requires ex-vivo complement inhibitors. |
Accelerate Your Complement Diagnostic Development with CamelBio
Designing robust complement immunoassays requires high-affinity neo-epitope antibodies, properly folded recombinant controls, and careful assay validation. CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—supporting your assay pipeline every step of the way from concept to clinic.
Whether you need optimized C3a/C5a calibrators or specialized C5b-9 neo-epitope antibodies, our technical team is ready to empower your immunoassay performance.
Contact CamelBio today to request samples and consult with our IVD experts.